Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Chiappori · SciRah

Researcher profile · Semantic Scholar

A. Chiappori

Share profile

A. Chiappori — researcher profile on SciRah

h-index: 49
Works: 233
Citations: 14K

Most-cited papers

Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer
S. Antonia, A. Villegas, D. Daniel, D. Vicente +26 more
2017New England Journal of Medicine2,703 citations Open access
Semantic Scholar
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. Antonia, A. Villegas, D. Daniel, D. Vicente +29 more
2018New England Journal of Medicine2,405 citations Open access
Semantic Scholar
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
J. Gray, A. Villegas, D. Daniel, D. Vicente +16 more
2019Journal of Thoracic Oncology380 citations Open access
Semantic Scholar
Tumor-infiltrating lymphocyte treatment for anti-PD-1 resistant metastatic lung cancer: a phase I trial
B. Creelan, chao wang, J. Teer, E. Toloza +22 more
2021Nature Medicine379 citations Open access
Semantic Scholar
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Pietanza, S. Waqar, L. Krug, A. Dowlati +20 more
2018Journal of Clinical Oncology341 citations Open access
Semantic Scholar
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
L. Horn, Zi-Ping Wang, Gang Wu, E. Poddubskaya +19 more
2021JAMA Oncology238 citations Open access
Semantic Scholar
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
N. Roper, M. Velez, A. Chiappori, Yoo Sun Kim +14 more
2021Nature Communications140 citations Open access
Semantic Scholar
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
R. Hui, M. Özgüroğlu, A. Villegas, D. Daniel +14 more
2019The Lancet Oncology135 citations Open access
Semantic Scholar
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
A. Saltos, M. Shafique, A. Chiappori
2020Frontiers in Oncology132 citations Open access
Semantic Scholar
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.
T. Owonikoko, H. Niu, K. Nackaerts, T. Csőszi +32 more
2020Journal of Thoracic Oncology119 citations Open access
Semantic Scholar
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
S. Aix, T. Ciuleanu, A. Navarro, S. Cousin +29 more
2022The Lancet Respiratory Medicine104 citations Open access
Semantic Scholar
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
Melanie Mediavilla-Varela, J. Castro, A. Chiappori, D. Noyes +4 more
2017Neoplasia85 citations Open access
Semantic Scholar
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
A. Chiappori, Charles C. Williams, J. Gray, T. Tanvetyanon +8 more
2018Cancer Immunology and Immunotherapy63 citations Open access
Semantic Scholar
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
O. Hamid, A. Chiappori, John A. Thompson, T. Doi +14 more
2022Journal for ImmunoTherapy of Cancer52 citations Open access
Semantic Scholar
Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer
A. Chiappori, B. Creelan, T. Tanvetyanon, J. Gray +14 more
2022Clinical Cancer Research50 citations Open access
Semantic Scholar
Loneliness as a mediator of the relationship of social cognitive variables with depressive symptoms and quality of life in lung cancer patients beginning treatment
K. Hyland, B. Small, J. Gray, A. Chiappori +6 more
2019Psycho-Oncology48 citations
Semantic Scholar
Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
J. Marin-Acevedo, B. Pellini, E. Kimbrough, J. K. Hicks +1 more
2023Cancers45 citations Open access
Semantic Scholar
Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms
Narges K. Tafreshi, D. Pandya, C. Tichacek, M. Budzevich +10 more
2021European Journal of Nuclear Medicine and Molecular Imaging44 citations
Semantic Scholar
Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer
B. Perez, Sungjune Kim, Min-Hsuan Wang, A. Karimi +21 more
2020International Journal of Radiation Oncology, Biology, Physics43 citations Open access
Semantic Scholar
ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3
G. Selvaggi, H. Wakelee, T. Mok, Y.-L. Wu +17 more
202042 citations Open access
Semantic Scholar
Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
A. Chiappori, Charles C. Williams, B. Creelan, T. Tanvetyanon +13 more
201842 citations
Semantic Scholar
CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
P. Gopalan, A. G. Villegas, Chun-Xia Cao, M. Pinder-Schenck +5 more
2018OncoTarget41 citations Open access
Semantic Scholar
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
J. Gray, A. Chiappori, Charles C. Williams, T. Tanvetyanon +14 more
2018Cancer Immunology and Immunotherapy35 citations Open access
Semantic Scholar
PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
L. Paz-Ares, T. Ciuleanu, A. Navarro, A. Fulop +19 more
2021Journal of Thoracic Oncology31 citations Open access
Semantic Scholar
697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC)
L. Byers, J. Heymach, D. Gibbons, Jian-Jun Zhang +5 more
2022Regular and Young Investigator Award Abstracts28 citations Open access
Semantic Scholar
Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
L. Byers, A. Chiappori, M. Smit
2019Journal of Clinical Oncology27 citations
Semantic Scholar
Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study
L. Aurisicchio, A. Fridman, D. Mauro, Rose Sheloditna +3 more
2020Journal of Translational Medicine26 citations Open access
Semantic Scholar
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
B. Creelan, J. Gray, T. Tanvetyanon, A. Chiappori +4 more
2019British Journal of Cancer25 citations Open access
Semantic Scholar
Three-year overall survival update from the PACIFIC trial.
J. Gray, A. Villegas, D. Daniel, D. Vicente +16 more
2019Journal of Clinical Oncology22 citations
Semantic Scholar
Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial
B. Creelan, chao wang, J. Teer, E. Toloza +17 more
2020Tumor Biology18 citations
Semantic Scholar
Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.
L. Byers, K. Gold, J. Peguero, M. Johnson +6 more
2021Journal of Clinical Oncology17 citations
Semantic Scholar
A Bayesian pick-the-winner design in a randomized phase II clinical trial.
Dung-Tsa Chen, Po-Yu Huang, Hui-Yi Lin, A. Chiappori +4 more
2017OncoTarget17 citations Open access
Semantic Scholar
Three-year overall survival update from the PACIFIC trial
Y.-L. Wu, J. Gray, A. Villegas, D. Daniel +16 more
2019Annals of Oncology16 citations Open access
Semantic Scholar
MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
D. Camidge, S. Gadgeel, S. Ou, L. Gandhi +15 more
201715 citations Open access
Semantic Scholar
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
C. Liveringhouse, K. Latifi, Amalin Asous, Nghi B. Lam +21 more
2023International Journal of Radiation Oncology, Biology, Physics14 citations
Semantic Scholar
A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses
T. Boyle, G. Quinn, M. Schabath, T. Muñoz-Antonia +17 more
2019Cancer Medicine14 citations Open access
Semantic Scholar
Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
S. Antonia, A. Villegas, D. Daniel, D. Vicente +28 more
2018Pneumologie12 citations Open access
Semantic Scholar
Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
L. Bazhenova, J. Hodgson, Corey J. Langer, G. Simon +15 more
201712 citations
Semantic Scholar
P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort
A. Chiappori, John A. Thompson, F. Eskens, J. Spano +14 more
2020Journal of Immunotherapy for Cancer10 citations Open access
Semantic Scholar
P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
A. Chiappori, Charles C. Williams, B. Creelan, T. Tanvetyanon +13 more
2018Journal of Thoracic Oncology10 citations Open access
Semantic Scholar
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
D. Planchard, B. Cho, J. Gray, L. Paz-Ares +14 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar
Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies
S. Fu, U. Banerji, Philippe Bédard, A. Ferrandiz +12 more
2022Cancer Research8 citations
Semantic Scholar
Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
Dung-Tsa Chen, W. Chan, Z. Thompson, R. Thapa +7 more
2021PLoS ONE8 citations Open access
Semantic Scholar
A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
B. Perez, S.-W. Kim, T. Dilling, K. Latifi +14 more
2019International Journal of Radiation Oncology, Biology, Physics8 citations Open access
Semantic Scholar
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
S. Ou, M. Socinski, S. Gadgeel, L. Gandhi +10 more
2018ESMO Open8 citations Open access
Semantic Scholar
Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model
Bhaswati Sarcar, Nicholas T. Gimbrone, G. Wright, L. L. Remsing Rix +7 more
2019FEBS Open Bio7 citations Open access
Semantic Scholar
Patient, Caregiver and Physician Perspectives on Participating in a Thoracic Rapid Tissue Donation Program
G. Quinn, R. Pentz, T. Muñoz-Antonia, T. Boyle +11 more
2017Patient Education and Counseling6 citations Open access
Semantic Scholar
LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
L. Paz-Ares, A. Villegas, D. Daniel, D. Baz +16 more
20176 citations Open access
Semantic Scholar
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
A. Saltos, B. Creelan, T. Tanvetyanon, A. Chiappori +10 more
2023Lung Cancer5 citations
Semantic Scholar
Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
Dung-Tsa Chen, A. Saltos, T. Rose, Z. Thompson +3 more
2023Cancers5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Gray×24
Invite
J. Gray — researcher profile on SciRah
S. Antonia×19
Invite
S. Antonia — researcher profile on SciRah
B. Creelan×16
Invite
B. Creelan — researcher profile on SciRah
E. Haura×16
Invite
E. Haura — researcher profile on SciRah

×13

Invite

T. Tanvetyanon — researcher profile on SciRah

L. Paz-Ares×10

Invite

L. Paz-Ares — researcher profile on SciRah

Invite

A. Villegas — researcher profile on SciRah

Invite

D. Daniel — researcher profile on SciRah

Invite

R. Hui — researcher profile on SciRah

Invite

B. Cho — researcher profile on SciRah

Invite

A. Saltos — researcher profile on SciRah

Dung-Tsa Chen×9

Invite

Dung-Tsa Chen — researcher profile on SciRah